Log in

Cogent Biosciences Stock Forecast, Price & News

+0.01 (+0.43 %)
(As of 10/5/2020)
Today's Range
Now: $2.35
50-Day Range
MA: $5.08
52-Week Range
Now: $2.35
Volume124,600 shs
Average Volume1.22 million shs
Market Capitalization$99.80 million
P/E RatioN/A
Dividend YieldN/A
Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.
Read More
Cogent Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.32 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:UMRX
Phone(617) 945-5576



Sales & Book Value

Annual Sales$22.50 million
Book Value$1.04 per share


Net Income$-31,830,000.00


Market Cap$99.80 million
Next Earnings DateN/A
OptionableNot Optionable
+0.01 (+0.43 %)
(As of 10/5/2020)
30 days | 90 days | 365 days | Advanced Chart

Receive UMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for UMRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Cogent Biosciences (NASDAQ:UMRX) Frequently Asked Questions

How has Cogent Biosciences' stock price been impacted by Coronavirus?

Cogent Biosciences' stock was trading at $0.3736 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UMRX shares have increased by 529.0% and is now trading at $2.35.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Cogent Biosciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cogent Biosciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cogent Biosciences?

Wall Street analysts have given Cogent Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cogent Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:UMRX) posted its earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.03. The company earned $0.53 million during the quarter. Cogent Biosciences had a negative return on equity of 87.78% and a negative net margin of 96.84%.
View Cogent Biosciences' earnings history

What price target have analysts set for UMRX?

4 analysts have issued 12 month price objectives for Cogent Biosciences' stock. Their forecasts range from $4.00 to $4.00. On average, they expect Cogent Biosciences' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 70.2% from the stock's current price.
View analysts' price targets for Cogent Biosciences

Who are some of Cogent Biosciences' key competitors?

What other stocks do shareholders of Cogent Biosciences own?

Who are Cogent Biosciences' key executives?

Cogent Biosciences' management team includes the following people:
  • Andrew R. Robbins, President, Chief Executive Officer & Director
  • Geoffrey Hodge, Chief Technical Officer & Senior VP-Operations
  • John L. Green, Chief Financial & Accounting Officer
  • Jessica Sachs, Chief Medical Officer
  • Greg Motz, Head-Research

When did Cogent Biosciences IPO?

(UMRX) raised $75 million in an initial public offering on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

What is Cogent Biosciences' stock symbol?

Cogent Biosciences trades on the NASDAQ under the ticker symbol "UMRX."

How do I buy shares of Cogent Biosciences?

Shares of UMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cogent Biosciences' stock price today?

One share of UMRX stock can currently be purchased for approximately $2.35.

How big of a company is Cogent Biosciences?

Cogent Biosciences has a market capitalization of $99.80 million and generates $22.50 million in revenue each year. The company earns $-31,830,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. Cogent Biosciences employs 72 workers across the globe.

What is Cogent Biosciences' official website?

The official website for Cogent Biosciences is www.unumrx.com.

How can I contact Cogent Biosciences?

Cogent Biosciences' mailing address is 200 CAMBRIDGE PARK DRIVE SUITE 3100, CAMBRIDGE MA, 02140. The company can be reached via phone at (617) 945-5576 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.